Pathogenesis of Oncoviruses: A Systemic Review

키워드

참고문헌 (85)

1. Krump NA, "Molecular mechanisms of viral oncogenesis in humans", Nat. Rev. Microbiol, 16, pp.684~698 (2018)
2. de Martel C, "Global burden of cancer attributable to infections in 2018 : a worldwide incidence analysis", Lancet Glob. Health, 8, pp.e180~e190 (2020)
3. Plummer M, "Global burden of gastric cancer attributable to Helicobacter pylori", Int. J. Cancer, 136, pp.487~490 (2015)
4. Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide", J. Pathol, 189, pp.12~19 (1999)
5. "Cancer statistics CDC"[URL]
6. Fugl A, "Epstein-Barr virus and its association with disease - a review of relevance to general practice", BMC Fam. Pract, 20, pp.62~ (2019)
7. Epstein MA, "Virus particles in cultured lymphoblasts from Burkitt’s lymphoma", Lancet, 1, pp.702~703 (1964)
8. Zur Hausen H, "Cancer “Causation” by infections-individual contributions and synergistic networks", Semin. Oncol, 41, pp.860~875 (2014)
9. Chang MH, "Decreased incidence of hepatocellular carcinoma in Hepatitis B vaccinees: A 20-year follow-up study", J. Natl. Cancer Inst, 101, pp.1348~1355 (2009)
10. Lu T, "Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection", World J. Gastroenterol, 19, pp.8887~8894 (2013)
11. Joura EA, "Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease:retrospective pooled analysis of trial data", BMJ, 344, pp.e1401~ (2012)
12. Crosbie EJ, "Human papillomavirus and cervical cancer", Lancet, 382, pp.889~899 (2013)
13. Chang MH, "Hepatitis B virus and cancer prevention", Recent Results Cancer Res, 188, pp.75~84 (2011)
14. Yasunaga JI, "Oncogenic spiral by infectious pathogens: Cooperation of multiple factors in cancer development", Cancer Sci, 109, pp.24~32 (2018)
15. Plummer M, "Global burden of cancers attributable to infections in 2012:a synthetic analysis", Lancet Glob. Health, 4, pp.e609~e616 (2016)
16. Biological agents, "IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B", 1~475 (2023)
17. Ahmed HG, "Prevalence of human papillomavirus subtypes 16 and 18 among Yemeni patients with cervical cancer", Asian Pac. J. Cancer Prev, 18, pp.1543~1548 (2017)
18. Steben M, "Human papillomavirus infection:epidemiology and pathophysiology", Gynecol. Oncol, 107, pp.S2~S5 (2007)
19. Teufel A, "Genetics of hepatocellular carcinoma", World J. Gastroenterol, 13, pp.2271~2282 (2007)
20. Hamdane N, "HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response", Gastroenterology, 156, pp.2313~2329 (2019)
21. Lin MV, "Hepatitis C virus-associated cancer", Ann. Rev. Pathol, 10, pp.345~370 (2015)
22. Goncalves PH, "Kaposi sarcoma herpesvirus-associated cancers and related diseases", Curr. Opin. HIV AIDS, 12, pp.47~56 (2017)
23. Guasparri I, "KSHV vFLIP is essential for the survival of infected lymphoma cells", J. Exp. Med, 199, pp.993~1003 (2004)
24. Casper C, "KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine", NPJ Vaccines, 7, pp.108~ (2022)
25. Panfil AR, "Human T-cell leukemia virus-associated malignancy", Curr. Opin. Virol, 20, pp.40~46 (2016)
26. DeCaprio JA, "Merkel cell polyomavirus and Merkel cell carcinoma", Philos. Trans. R Soc. Lond. B Biol. Sci, 372, pp.20160276~ (2017)
27. Bakkalci D, "Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence", J. Glob. Health, 10, pp.010405~ (2020)
28. Bansal A, "Human papillomavirus-associated cancers: A growing global problem", Int. J. Appl. Basic Med. Res, 6, pp.84~89 (2016)
29. Wiest T, "Involvement of intact HPV16 E6", E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control, 2002, pp.21, 1510~1517
30. Ganem D, "Viral Hepatitis B and C Detection among Ebola Survivors and Health Care Workers in Makeni, Sierra Leone", pp.4~ (2020), Fields Virology
31. Liang TJ, "Hepatitis B : the virus and disease", Hepatology, 49, pp.S13~S21 (2009)
32. Gavilanes F, "Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins", J. Biol. Chem, 257, pp.7770~7777 (1982)
33. Gerlich WH, "Hepatitis B virus contains protein attached to the 5' terminus of its complete DNA strand", Cell, 21, pp.801~809 (1980)
34. Hruska JF, "Structure of hepatitis B Dane particle DNA before and after the Dane particle DNA polymerase reaction", J. Virol, 21, pp.666~672 (1977)
35. Liaw Y-F, "Hepatitis B virus infection", Lancet, 373, pp.582~592 (2009)
36. Nelson NP, "Epidemiology of Hepatitis B virus infection and impact of vaccination on disease", Clin. Liver Dis, 20, pp.607~628 (2016)
37. Lim JK, "Prevalence of chronic Hepatitis B virus infection in the United States", Am. J. Gastroenterol, 115, pp.1492~1438 (2020)
38. Peng CY, "Hepatitis B virus-related decompensated liver cirrhosis : benefits of antiviral therapy", J. Hepatol, 57, pp.442~450 (2012)
39. Arbuthnot P, "Hepatitis B virus and hepatocellular carcinoma", Int. J. Exper. Pathol, 82, pp.77~100 (2001)
40. El-Serag HB, "Hepatocellular carcinoma : Epidemiology and molecular carcinogenesis", Gastroenterology, 132, pp.2557~2576 (2007)
41. Levrero M, "Mechanisms of HBV-induced hepatocellular carcinoma", J. Hepatol, 64, pp.S84~S101 (2016)
42. Venook AP, "The incidence and epidemiology of hepatocellular carcinoma : a global and regional perspective", Oncologist, 15, pp.5~13 (2010)
43. Pietschmann T, "Hepatitis C Virus", Trends Microbiol, 27, pp.379~380 (2019)
44. Tibbs CJ, "Methods of transmission of hepatitis C", J. Viral Hepat, 2, pp.113~119 (1995)
45. Niederau C, "Prognosis of chronic hepatitis c: Results of a large, prospective cohort study", Hepatology, 28, pp.1687~1695 (1998)
46. Khullar V, "Hepatitis C cirrhosis : New perspectives for diagnosis and treatment", World J. Hepatol, 7, pp.1843~1855 (2015)
47. Rehermann B, "Immunology of hepatitis B virus and hepatitis C virus infection", Nat. Rev. Immunol, 5, pp.215~229 (2005)
48. Hanahan D, "Hallmarks of cancer : The next generation", Cell, 144, pp.646~674 (2011)
49. Arzumanyan A, "Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma", Nat. Rev. Cancer, 13, pp.123~135 (2013)
50. Levrero M, "Control of cccDNA function in hepatitis B virus infection", J. Hepatol, 51, pp.581~592 (2009)
51. Hoshida Y, "Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma", J. Hepatol, 61, pp.S79~S90 (2014)
52. Yarchoan R, "HIV-associated cancers and related diseases", New Eng. J. Med, 378, pp.1029~1041 (2018)
53. Repáraz D, "Therapeutic vaccines against hepatocellular carcinoma in the immune checkpoint inhibitor era: Time for neoantigens?", Int. J. Mol. Sci, 23, pp.2022~ (2022)
54. Mesri EA, "Kaposi’s sarcoma and its associated herpesvirus", Nat. Rev. Cancer, 10, pp.707~719 (2010)
55. Chakraborty S, "Kaposi’s Sarcoma associated herpesvirus entry into target cells", Front. Microbiol, 3, pp.6~ (2012)
56. Sharma-Walia N, "Kaposi’s Sarcoma associated Herpes virus(KSHV)induced COX-2 : A key factor in latency, inflammation, angiogenesis, cell survival and invasion", PLoS Pathog, 6, pp.e1000777~ (2010)
57. Samji H, "Closing the gap : increases in life expectancy among treated HIV-positive individuals in the United States and Canada", PLoS One, 8, pp.e81355~ (2013)
58. Oksenhendler E, "Multicentric Castleman's disease in HIV infection : a clinical and pathological study of 20 patients", AIDS, 10, pp.61~67 (1996)
59. Lurain K, "Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease", Hematol. Oncol. Clin, 32, pp.75~88 (2018)
60. Tagaya Y, "40 years of the human T-cell leukemia virus: past, present, and future", F1000Res, 8, pp.F1000~ (2019)
61. Matsuoka M, "Human T-cell leukaemia virus type 1(HTLV-1)infectivity and cellular transformation", Nat. Rev. Cancer, 7, pp.270~280 (2007)
62. Marino-Merlo F, "Antiretroviral therapy in HTLV-1 infection : an updated overview", Pathogens, 9, pp.342~ (2020)
63. Bangham CR, "Regulation of latency in the human T cell leukemia virus, HTLV-1", Ann. Rev. Virol, 6, pp.365~385 (2019)
64. Tu JJ, "The past, present, and future of a human T-cell leukemia virus type 1 vaccine", Front. Microbiol, 13, pp.897346~ (2022)
65. Arnold J, "Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation", Blood, 112, pp.3788~3797 (2008)
66. Spurgeon ME, "Merkel cell polyomavirus : A newly discovered human virus with oncogenic potential", Virology, 435, pp.118~130 (2013)
67. Stakaitytė G, "Merkel cell polyomavirus : Molecular insights into the most recently discovered human tumour virus", Cancers, 6, pp.1267~1297 (2014)
68. DeCaprio JA, "Molecular pathogenesis of Merkel cell carcinoma", Ann. Rev. Pathol, 16, pp.69~91 (2021)
69. Hesbacher S, "RB1 is the crucial target of the Merkel cell polyomavirus large T antigen in Merkel cell carcinoma cells", Oncotarget, 7, pp.32956~32968 (2016)
70. Patel P, "Radiotherapy for inoperable Merkel cell carcinoma : a systematic review and pooled analysis", Dermatol. Pract. Concept, 8, pp.149~ (2018)
71. Walocko FM, "Metastatic Merkel cell carcinoma response to nivolumab", J. Immunother. Cancer, 4, pp.79~ (2016)
72. Haley CT, "Human oncoviruses : Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention : papillomaviruses and Merkel cell polyomavirus", J. Am. Acad. Dermatol, 81, pp.1~21 (2019)
73. Bjornevik K, "Epstein-Barr virus as a leading cause of multiple sclerosis : mechanisms and implications", Nat. Rev. Neurol, 19, pp.160~171 (2023)
74. Zeng Y, "LMP2-DC vaccine elicits specific EBV-LMP2 response to effectively improve immunotherapy in patients with nasopharyngeal cancer", Biomed. Environ. Sci, 33, pp.849~856 (2020)
75. Nickles E, "Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit", Cancer Immunol. Immunother, 71, pp.1531~1543 (2022)
76. Wang X, "Bromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replication", PLoS Pathog, 8, pp.e1003021~ (2012)
77. Prabhu SR, "Evidence of epstein-barr virus association with head and neck cancers: a review", J. Can. Assoc, 82, pp.g2~ (2016)
78. Tempera I, "Epigenetic regulation of EBV persistence and oncogenesis", Semin. Cancer Biol, 26, pp.22~29 (2014)
79. Fox RI, "Potential role of Epstein-Barr virus in Sjögren's syndrome and rheumatoid arthritis", J. Rheumatol. Suppl, 32, pp.18~24 (1992)
80. Rickinson AB, "Co-infections, inflammation and oncogenesis : Future directions for EBV research", Semin. Cancer Biol, 26, pp.99~115 (2014)
81. Kombe Kombe AJ, "Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation", Front. Public Health, 8, pp.552028~ (2021)
82. Narisawa-Saito M, "Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis : Roles of E6 and E7 proteins", Cancer Sci, 98, pp.1505~1511 (2007)
83. de Freitas AC, "hrHPV E5 oncoprotein : immune evasion and related immunotherapies", J. Exper. Clin. Cancer Res, 36, pp.71~ (2017)
84. Wang X, "Involvement of human papillomaviruses in cervical cancer", Front. Microbiol, 9, pp.2896~ (2018)
85. Howley PM, "Warts, cancer and ubiquitylation : lessons from the papillomaviruses", Trans. Am. Clin. Climatol. Assoc, 117, pp.113~127 (2006)

관련 논문AI추천